Liposarcoma is one of the most common soft tissue sarcomas, accounting for approximately 25% of all soft tissue sarcoma cases. overall 5-year survival rates are 90% and 30%, respectively, indicating that DDLPS is clinically more aggressive. We examined whether adipogenic stimulation induces adipogenesis in human WDLPS/DDLPS cells by using dexamethasone, indomethacin, insulin, and 3-isobutyl-1-methylxanthine (IBMX), all putative medications or drugs.
| INTRODUC TI ON
Liposarcoma is one of the most common soft tissue sarcomas, accounting for approximately 25% of all soft tissue sarcoma cases. 1 LPS is classified into four subtypes: WDLPS, DDLPS, myxoid/round cell LPS, and pleomorphic LPS. 1 WDLPS and DDLPS are the most common types of LPS (88%) and contain supernumerary ring and/or giant rod chromosomes formed by the amplification of chromosome 12q13-15, which contains several hundred genes including MDM2
and CDK4. 2 Overall 5-year survival rates of WDLPS and DDLPS patients are 90% and 30%, respectively, suggesting that DDLPS is clinically more aggressive than WDLPS. 3 Radical surgery remains the predominant treatment for most forms of LPS, whereas more advanced or metastatic diseases are treated using systemic therapy. Recently, systemic therapy for WDLPS/DDLPS patients has included the following: 4, 5 (i) conventional cytotoxic chemotherapy; (ii) marine-derived drugs; (iii) tyrosine kinase receptor inhibitors; (iv) MDM2 or CDK4 antagonists;
(v) PPAR-γ agonists; and (vi) immunotherapy. Although cytotoxicbased chemotherapy tends to elicit a higher response rate in various adipogenesis in human WDLPS/DDLPS cells by using dexamethasone, indomethacin, insulin, and 3-isobutyl-1-methylxanthine (IBMX), all putative medications or drugs.
Functional in vitro experiments showed that treatment with these four compounds induced adipogenic potency by transcriptional and translational upregulation of genes related to the maintenance of stemness and adipogenic differentiation. Using in vivo xenograft models, we found that the induction of stemness and adipogenesis inhibited the tumorigenic potency of DDLPS. This study suggests a potential application of drug repositioning in which adipogenesis-inducing compounds could be used to treat DDLPS patients in a clinical setting.
K E Y W O R D S
adipogenesis, dedifferentiated liposarcoma, stemness, well-differentiated liposarcoma, xenograft sarcomas (45%), the overall objective response rate is low (12%) in the majority of advanced WDLPS/DDLPS cases. 6, 7 Eribulin, a marine-derived drug, has been approved for use as a second-line LPS treatment. 8 Pazopanib, a multi-targeted tyrosine kinase receptor inhibitor, has been approved for the treatment of advanced nonadipocytic soft tissue sarcomas. 9 Although the MDM2 antagonist, Nutlin 3A, was shown to inhibit the interaction between TP53 and MDM2 in preclinical LPS models, it showed toxicity in a neoadjuvant setting; clinical trials for several CDK4 antagonists are still incomplete. 10 Figure S1 ) using an AmpFLSTR Identifiler PCR Amplification Kit (Thermo Fisher Scientific). Mycoplasma contamination was not detected in any cells.
| Adipogenic differentiation assay
Cells were seeded into a 6-well plate in DMEM medium, which was then replaced with an adipogenic differentiation medium ( A more detailed version of materials and methods is included in Data S1.
| RE SULTS

| Growth inhibition of human WDLPS/DDLPS cells by inducing adipogenesis in vitro
To 
| Inhibition of human DDLPS growth by inducing adipogenesis in vivo
To evaluate the antitumorigenic effect of treatment with adipogenesis-inducing compounds in vivo, LIPO-246, LIPO-863B, and LP6 
| D ISCUSS I ON
Although DDLPS patients receive intensive treatment such as radical surgery and systemic therapy, their overall 5-year survival rate is only 30%. 3 It has been shown that in vitro, PPAR-γ plays a role in the mechanism that reverts the DDLPS subtype to a well-differentiated LPS subtype associated with a potentially milder disease course; therefore, several clinical trials of PPAR-γ agonists have been conducted in LPS patients. 12, 21 However, these studies have shown that antitumor activity only occurs in myxoid and pleomorphic LPS subtypes and that the agonists have mixed effects in LPS patients. [12] [13] [14] Therefore, the DDLPS subtype is currently very challenging to treat and a novel systemic DDLPS therapy is needed.
Differentiation therapy emerged from several reports in the 1980s that stated that hormones and cytokines may enhance differentiation ex vivo in acute myeloid leukemia (AML). Currently, this concept is successfully used in AML treatment by combining retinoic acid and arsenic. 22 Recently, drugs have been discovered which promote differentiation in nasopharyngeal carcinoma, thyroid cancer, melanoma, glioma, cholangiocarcinoma, and sarcoma, and it has been suggested that they are worthy of clinical trials. 23 In the present study, we examined whether WDLPS/DDLPS cells can be converted into a more differentiated phenotype by adipogenic differentiation.
It is well known that the four compounds, dexamethasone, IBMX, indomethacin, and insulin, can induce adipogenic differentiation of human bone marrow stem cells. 19 Importantly, these compounds have been used to treat conditions such as immune system disorders.
We first found that these four compounds can induce adipogenic Based on their utility as treatments and the findings of our in vitro and in vivo experiments, we suggest that these adipogenesis-inducing drugs could be repositioned to treat DDLPS patients in a clinical setting.
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